OverviewSuggest Edit

In two facilities with combined manufacturing, packaging and laboratory capacity exceeding 170,000 sq. ft., ANI develops and manufactures liquid, powder and oral solid dose products, including those requiring containment. The Company also performs contract manufacturing for some of the largest and most respected pharmaceutical companies in the world. The fully-cGMP qualified facilities boast state-of-the-art analytical and stability laboratories for its rapidly expanding research and development program. 
TypePublic
Founded1996
HQBaudette, MN, US
Websiteanipharmaceuticals.com
Employee Ratings3.7
Overall CultureD

Latest Updates

Employees (est.) (Dec 2019)338(+14%)
Job Openings9
Revenue (FY, 2020)$208.5 M
Share Price (Sept 2021)$31.8(+6%)
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at ANI Pharmaceuticals

David B. Nash

David B. Nash

Director
Ori Gutwerg

Ori Gutwerg

Senior Vice President of Generics
Antonio Pera

Antonio Pera

Director
Nikhil Lalwani

Nikhil Lalwani

Director and President and CEO
Jeanne Thoma

Jeanne Thoma

Director
Stephen P. Carey

Stephen P. Carey

Vice President and Chief Financial Officer
Show more

ANI Pharmaceuticals Office Locations

ANI Pharmaceuticals has offices in Baudette and Oakville
Baudette, MN, US (HQ)
210 Main St W
Baudette, MN, US
455 Idc Rd SW
Oakville, CA
400 Iroquois Shore Rd
Show all (3)

ANI Pharmaceuticals Financials and Metrics

ANI Pharmaceuticals Revenue

ANI Pharmaceuticals's revenue was reported to be $208.48 m in FY, 2020
USD

Revenue (Q1, 2021)

54.5m

Gross profit (Q1, 2021)

34.5m

Gross profit margin (Q1, 2021), %

63.3%

Net income (Q1, 2021)

86.0k

EBIT (Q1, 2021)

3.0m

Market capitalization (23-Sept-2021)

383.7m

Closing stock price (23-Sept-2021)

31.8

Cash (31-Mar-2021)

25.1m

EV

542.0m
ANI Pharmaceuticals's current market capitalization is $383.7 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

435.2k2.3m30.1m56.0m76.3m128.6m176.8m201.6m206.5m208.5m

Revenue growth, %

86%36%69%

Cost of goods sold

10.0m11.5m12.7m48.8m79.0m73.0m63.2m87.2m

Gross profit

20.1m44.5m63.6m79.8m97.8m128.6m143.4m121.3m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

81.0k182.8k114.0k108.8k110.4k145.0k6.2m7.8m10.9m6.6m17.4m18.8m19.5m20.0m20.6m31.3m38.5m36.6m44.8m48.2m46.5m47.3m50.7m52.9m54.4m51.3m49.8m48.5m53.0m54.5m

Cost of goods sold

2.1m2.6m2.6m2.1m3.1m2.8m3.1m3.3m3.4m11.8m16.7m16.4m21.1m21.1m20.7m16.6m15.6m14.7m15.6m15.0m21.8m20.7m20.1m20.0m

Gross profit

4.1m5.2m8.3m4.5m14.3m16.0m16.4m16.7m17.1m19.5m21.9m20.2m23.6m27.1m25.8m30.7m35.1m38.2m38.7m36.3m28.0m27.8m32.9m34.5m

Gross profit Margin, %

66%66%76%68%82%85%84%84%83%62%57%55%53%56%55%65%69%72%71%71%56%57%62%63%
USDQ2, 2011

Financial Leverage

3.7 x
Show all financial metrics

ANI Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

C

72/100

SecurityScorecard logo

ANI Pharmaceuticals Online and Social Media Presence

Embed Graph

ANI Pharmaceuticals Company Culture

  • Overall Culture

    D

    57/100

  • CEO Rating

    A+

    90/100

  • Compensation

    D

    55/100

Learn more on Comparably

ANI Pharmaceuticals News and Updates

ANI Pharmaceuticals Announces Acquisition of Fluconazole Tablets

BAUDETTE, Minn., July 6, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the acquisition of Fluconazole Tablets USP, 50mg, 100mg, 150mg, and 200mg from a private company for $3.0 million. The current annual U.S. market for this product is...

Edge Pharma Completes Supplier Agreement with ANI Pharmaceuticals, Inc

COLCHESTER, Vt., June 25, 2020 /PRNewswire/ -- Edge Pharma has signed an agreement with ANI Pharmaceuticals to market the company's FDA approved Vancomycin Hydrochloride for Oral Solution USP, a generic equivalent to Vancocin®. The specific focus will be the hospital outpatient pharmacy...

ANI Pharmaceuticals Announces Launch of Bretylium Tosylate Injection, USP 50 mg/mL

BAUDETTE, Minn., Dec. 18, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Bretylium Tosylate Injection USP, 50 mg/mL. Bretylium Tosylate is a class III antiarrhythmic medication approved for the treatment of ventricular fibrillation and...

ANI Pharmaceuticals to Present at Evercore ISI 2nd Annual HealthCONx Conference

BAUDETTE, Minn., Nov. 26, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will present on December 3, 2019 at the Evercore ISI HealthCONx Conference in Boston, Massachusetts. Arthur Przybyl, President and CEO, Robert Schrepfer, Senior Vice President Business Development &...

ANI Pharmaceuticals Announces Approval of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5ml

BAUDETTE, Minn., June 20, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has received FDA approval of its Prior Approval Supplement for Vancomycin Hydrochloride for Oral Solution USP, 250 mg/5 ml, indicated for the treatment of various...

ANI Pharmaceuticals Expands Injectable Portfolio with Distribution Agreement for FDA Approved Injectable Product

Key terms of the 10-year Agreement include cumulative milestones of up to $2M, payable by ANI. Upon launch, ANI will receive a 50% share of net profits generated from product revenues. The product, for which there are currently no other generics commercially available, recently received FDA approval…
Show more

ANI Pharmaceuticals Frequently Asked Questions

  • When was ANI Pharmaceuticals founded?

    ANI Pharmaceuticals was founded in 1996.

  • Who are ANI Pharmaceuticals key executives?

    ANI Pharmaceuticals's key executives are David B. Nash, Ori Gutwerg and Antonio Pera.

  • How many employees does ANI Pharmaceuticals have?

    ANI Pharmaceuticals has 338 employees.

  • What is ANI Pharmaceuticals revenue?

    Latest ANI Pharmaceuticals annual revenue is $208.5 m.

  • What is ANI Pharmaceuticals revenue per employee?

    Latest ANI Pharmaceuticals revenue per employee is $616.8 k.

  • Who are ANI Pharmaceuticals competitors?

    Competitors of ANI Pharmaceuticals include Biosearch Life, Cue Biopharma and Oxurion.

  • Where is ANI Pharmaceuticals headquarters?

    ANI Pharmaceuticals headquarters is located at 210 Main St W, Baudette.

  • Where are ANI Pharmaceuticals offices?

    ANI Pharmaceuticals has offices in Baudette and Oakville.

  • How many offices does ANI Pharmaceuticals have?

    ANI Pharmaceuticals has 3 offices.